Trade Names:Azactam- Powder for injection (lyophilized cake) 500 mg (with approximately 780 mg L-arginine per gram aztreonam)- Powder for injection (lyophilized cake) 1 g (with approximately 780 mg L-arginine per gram aztreonam)- Powder for injection (lyophilized cake) 2 g (with approximately 780 mg L-arginine per gram aztreonam)- Solution for injection 1 g per 50 mL- Solution for injection 2 g per 50 mL
Inhibits bacterial cell wall synthesis.
C max is 54 mcg/mL (500 mg dose), 90 mcg/mL (1 g dose); and 204 mcg/mL (2 g dose) immediately after administration.IM
T max is approximately 1 h; produces comparable serum concentrations to IV doses.
Vd is approximately 12.6 L; approximately 56% protein bound. Widely distributed to fluids and tissues, including CSF (inflamed meninges) and breast milk; crosses placenta.
The t ½ is approximately 1.7 h; serum clearance is 91 mL/min; renal clearance is 56 mL/min; 60% to 70% is recovered in the urine by 8 h; approximately 12% recovered in the feces.
Serum t ½ may be prolonged.Hepatic Function Impairment
Serum t ½ may be prolonged.Elderly
Serum t ½ may be prolonged.
Treatment of infections of urinary tract, lower respiratory tract, skin and skin structure, intra-abdominal infections, gynecologic infections, surgical infections, and septicemia caused by susceptible microorganisms.
Treatment of acute, uncomplicated gonorrhea in patients with penicillin-resistant gonococci.
IM/IV 500 mg or 1 g every 8 to 12 h.Systemic InfectionsAdults
IM/IV 1 to 2 g every 6 to 12 h.Children
IM/IV 30 to 50 mg/kg every 4 to 8 h.Acute Uncomplicated Gonorrhea
IM 1 g. Max recommended dosage is 8 g/day.
Shake reconstituted solutions vigorously immediately after mixing. Reconstituted solutions not exceeding 2% are stable at room temperature for 48 h; stable under refrigeration for 7 days. Discard unused solutions. See the prescribing information for further storage and incompatibility information. Frozen infusion solutions may be stored for up to 3 mo at −4°F.
May antagonize activity of aztreonam and should not be used concurrently.
Nafcillin sodium, cephradine, and metronidazole are incompatible in admixture.
15% to 20% of patients had elevations of AST and ALT more than 3 times the ULN.
Diarrhea; nausea; vomiting; pseudomembranous colitis.
Phlebitis/thrombophlebitis after IV administration; pain/swelling at IM injection site; fever.
Review culture and sensitivity of organism as available.
Category B .
Excreted in breast milk.
Safety and efficacy in children younger than 9 mo of age not established.
Reactions range from mild to life-threatening. Administer cautiously to penicillin- or cephalosporin-sensitive patients because of possible cross-reactivity.
Reduced dose required.
May result in overgrowth of nonsusceptible bacterial or fungal organisms.
Copyright © 2009 Wolters Kluwer Health.